Phorum

Drug Substance

Changes to BioPhorum extractables protocol

The BioPhorum Extractables team has shown the benefits of great collaboration between biomanufacturers and suppliers – they agreed to significantly reduce extractables testing for single-use systems. This decision was made possible by the supply base’s considerable body of data generated through the existing protocol and the biomanufacturer team’s work over the last 12 months. Similar studies have been performed previously, but typically with a smaller or partial data set and crucially without biomanufacturer involvement.

 

The outcome of this data-driven review process is that the BioPhorum biomanufacturer members have chosen to remove two solvents (NaCl and PS80) as well as revise the requirements for testing at time point zero and for elemental impurities. The team is busy writing up these changes and aims to publish in Q1 2020. As a second step, the team has also looked at the requirements for testing on different types of components and increased granularity will be created. These recommendations are still being finalized but should also reduce the extractables testing required by the industry.

Overall, the team believes that these changes do not represent any erosion of the high standards for patient safety, but instead provide a data-based rationale for where testing is and is not adding value but adding time and cost. Streamlined extractables testing will allow biomanufacturers and supply partners to focus resource where it is most valuable, ultimately supporting industry innovation.

If you are currently in the process of planning an extractables study, please contact your BioPhorum team member or register your interest here :

  • By submitting this form you will be added to our updates mailing list for the Extractables and Leachables resource.
  • You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

  • This field is for validation purposes and should be left unchanged.
  • Contact address

    BioPhorum
    The Gridiron Building
    One Pancras Square
    London
    N1C 4AG

    Newsletter subscribe

    You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



    © 2019 Biophorum Operations Group · All Rights Reserved

    Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

    Company Number 06794795 · VAT Number GB298617544

    Driving progress in Cell & Gene Therapy

    Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

    Read More
    Cell and Gene Therapy Phorum accelerates progress

    The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

    Read More
    2018 highlights

    BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

    Read More
    Sharing powerful collaboration data on the impact of resin cycling on viral clearance

    A crucial issue for biotechnology products is that the mammalian cell lines commonly used in manufacturing are susceptible to viral contamination. Therefore, demonstration of viral[...]

    Read More
    Industry bioassay approach helps to shape the future

    In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

    Read More
    Sharing ideas on forced degradation

    “Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

    Read More
    Delivering globally on in-line monitoring and real-time release

    BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in[...]

    Read More
    New and improved User Requirements Toolkit for single-use systems

    To help customers and manufacturers achieve a ‘right first time’ implementation of single-use systems, BioPhorum launched a User Requirements Toolkit in June 2018. This includes[...]

    Read More
    Why raw materials are the unsung heroes of human medicinal product manufacturing

    “It’s not easy being a biopharmaceutical raw material…” So says Kara Stockett Quinn of Merck & Co. In a recent American Pharmaceutical Review article, Quinn[...]

    Read More
    PUPSIT – An update on BioPhorum/PDA work to develop a risk-based position
    Read More
    Driving the evolution of secondary packaging

    How do we transition from large-batch manufacture to small-batch, high-value packaging runs?

    Read More
    Hi-tech ambitions for Fill Finish

    The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

    Read More
    Logistics collaboration hub: An opportunity for significant time and cost savings

    Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

    Read More
    The ‘how to’ guide to implementing Agile in GxP

    The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

    Read More
    How smart is your maintenance?

    Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

    Read More
    BioPhorum’s Maturity Assessment Tool gains momentum
    Read More
    Supply chain, forecasting and demand planning solutions gain momentum

    The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

    Read More
    2018 highlights

    BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

    Read More
    Delivering globally on in-line monitoring and real-time release

    BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in[...]

    Read More
    Removing the roadblocks to continuous biomanufacturing

    Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

    Read More
    Changing mindsets with a modular approach

    Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

    Read More
    Slicing years off change implementation

    As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

    Read More
    BioPhorum Regulatory Interaction: helping to open doors

    To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

    Read More
    Regulatory compliance: what lessons can be learned?

    BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

    Read More
    Navigating the maze of medical technology regulation: a solo voyage or a team effort?

    Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

    Read More

    IaaS Cloud webinar recording play back
    Read More
    New BPIT guidance to align cloud services to regulatory requirements
    Read More
    Data Integrity and Agile Webinars to support industry response to regulators
    Read More
    How to validate informatics in CPV programs

    The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

    Read More
    Continued Process Verification delivering real saving in time and money

    More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

    Read More
    A roadmap for the implementation of continued process verification

    This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

    Read More
    How smart is your maintenance?

    Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

    Read More
    Digital plant maturity model webinar replay
    Read More
    Digital Plant Maturity Model workstream to host webinar
    Read More
    New guidance available on Forecasting and Demand Planning to streamline supply chain performance
    Read More
    Changes to BioPhorum extractables protocol

    The BioPhorum Extractables team has shown the benefits of great collaboration between biomanufacturers and suppliers – they agreed to significantly reduce extractables testing for single use[...]

    Read More
    Host cell proteins poster

    This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

    Read More
    Host cell protein risk assessment, an industry approach

    Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

    Read More
    BEBPA risk assessment workshop
    Read More
    New and improved User Requirements Toolkit for single-use systems

    To help customers and manufacturers achieve a ‘right first time’ implementation of single-use systems, BioPhorum launched a User Requirements Toolkit in June 2018. This includes[...]

    Read More
    What is BioPhorum and how does it work
    Read More
    Overview of the BioPhorum Technology Roadmap
    Read More
    Japan’s bioeconomy strategy objectives and principles
    Read More